Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement

Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement

ORLANDO, Fla., April 12, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM, its proprietary formulation of lower-dose naltrexone, today announced, that it has further strengthened its balance sheet by settling an outstanding long-term debt. As a result, the Company has settled the majority of its outstanding convertible long-term debt, putting the Company on firm financial ground to move ahead with its business plan.

Read More
Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio

Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio

ORLANDO, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM, its proprietary form of lower-dose naltrexone, today announced it has filed three new patent applications in the US in the last four months with the latest being the Company's PTC patent for Method for Sustained Immune Response filed March 23, 2017.

Read More